anti-c-erb-B2 antibodies (Institute of Cancer Research)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-c-erb-B2 antibodies (Institute of Cancer Research)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesInstitute Of Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInstitute Of Cancer Research
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A